Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines (NASDAQ: GENB) plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generate Biomedicines (NASDAQ: GENB) plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026.
A live webcast and an archived replay are expected to be available on the company’s investor website under Events and Presentations.
Details
News Market Reaction – GENB
On May 29, the first trading day after this news, GENB closed 0.23% above the previous close.
Data tracked by StockTitan Argus for the May 29 session.
Key Figures
- Conference date
- June 8, 2026
- Goldman Sachs Global Healthcare Conference participation
- Current price
- $13.09
- Pre-news close on analysis date
- 24h price change
- -1.95%
- Move prior to conference announcement
- 52-week high
- $16.7484
- Upper end of 52-week trading range
- 52-week low
- $11.00
- Lower end of 52-week trading range
- Market cap
- $1,676,757,691
- Pre-news market capitalization
Historical Context
-
Q1 2026 loss of $61.7M offset by strong $516.6M cash position.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast is expected to be available in the Events and Presentations section of the Company's investor website at investors.generatebiomedicines.com. An archived replay is also expected to be available following the presentation.
About Generate:Biomedicines
Generate (NASDAQ: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com, or follow us on X, LinkedIn, and YouTube.
Generate Media Contact
Megan McLaughlin
pr@generatebiomedicines.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/generate-biomedicines-inc-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-302785001.html
SOURCE Generate:Biomedicines
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.